ProQR Therapeutics (PRQR) Total Liabilities (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Total Liabilities for 15 consecutive years, with $69.9 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 15.56% year-over-year to $69.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.9 million (down 15.56% YoY) and the FY2025 annual result came in at $72.1 million, down 20.17% from the prior year.
• Total Liabilities fell to $69.9 million in Q1 2026 per PRQR's latest filing, from $72.1 million in the prior quarter.
• Over the last five years, Total Liabilities for PRQR reached as high as $119.1 million in Q4 2022 and fell as low as $65.1 million in Q3 2022.
• A 5-year average of $93.9 million and a median of $97.0 million in 2024 frame the typical range for Total Liabilities.
• The largest YoY upside for Total Liabilities was 105.47% in 2022 against a maximum downside of 99.79% in 2022.
• Year by year, Total Liabilities stood at $119.1 million in 2022, then fell by 7.79% to $109.8 million in 2023, then slipped by 17.72% to $90.4 million in 2024, then retreated by 20.17% to $72.1 million in 2025, then declined by 3.07% to $69.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $69.9 million, $72.1 million, and $76.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.